| Old Articles: <Older 6331-6340 Newer> |
|---|
 |
The Motley Fool
May 18, 2010
Brian Orelli |
Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.   |
InternetNews
May 17, 2010 |
Data Breach Tags N.M. Medicaid Patients Nearly 10,000 participants in New Mexico's Medicaid program had their personal information compromised after a car with a laptop in the trunk was stolen in Chicago. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
The Motley Fool
May 14, 2010
Ryan McBride |
Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back. |
BusinessWeek
May 13, 2010
Jesse Drucker |
Forest Laboratories' Globe-Trotting Profits From New York to Dublin, through Amsterdam to Bermuda -- how one pharmaceutical company avoids a third of its U.S. income taxes by moving its money around the world |
BusinessWeek
May 13, 2010
Simeon Bennett |
Mobile Phones Fight Africa's Drug Wars New systems that let users dial up to verify antimalarial and other drugs' authenticity could be a major defense against counterfeit meds. |
The Motley Fool
May 12, 2010
Matt Koppenheffer |
Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround? |
The Motley Fool
May 12, 2010
Brian Orelli |
Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong. |
The Motley Fool
May 11, 2010
Brian Orelli |
Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40. |
The Motley Fool
May 11, 2010
Ryan McBride |
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals. |
| <Older 6331-6340 Newer> Return to current articles. |
